|
Procalcitonin levels, SOFA and APACHE II scores |
|||||||||
| Measurement |
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
Day 7 |
Day 8 |
ANOVA |
|
|
|||||||||
| PCT (ng/mL) |
|||||||||
| Pentaglobin® |
5.5 (0.9–72.0) |
3.5* (0.9–65.0) |
3.5** (0.9–39.0) |
3.05* (0.9–23.0) |
2.6* (0.8–11.0) |
2.45 (0.6–11.0) |
2.0* (0.6–11.0) |
1.45** (0.6–14.3) |
<0.001 |
| Control |
4.0 (0.4–194.0) |
3.14 (0.4–72.0) |
3.2 (0.2–34.0) |
2.65 (0.6–18.0) |
3.15 (0.5–14.0) |
4.0 (0.6–21.6) |
4.0 (0.3–117.0) |
4.0 (0.5–185.0) |
0.8 |
| SOFA |
|||||||||
| Pentaglobin® |
5.0 (1.0–10.0) |
6.0 (1.0–11.0) |
6.0 (0–12) |
5.0 (0–16) |
4.0 (0.0–16.0) |
4.0 (0–16) |
3.5 (0.0–15.0) |
4.0 (0–14) |
0.2 |
| Control |
4.5 (1.0–12.0) |
5.5 (1.0–15.0) |
5.0 (2–15) |
5.0 (2–12) |
4.5 (1.0–10.0) |
5.0 (1–11) |
4.0 (1.0–11.0) |
6.0 (0–10) |
0.3 |
| APACHE II |
|||||||||
| Pentaglobin® |
15.0 (9–24) |
14.0 (8.0–28.0) |
14.0 (7–24) |
13.0 (7–30) |
11.0 (5.0–30.0) |
11.5* (5.0–30.0) |
12.5 (5.0–30.0) |
8.0** (5–30) |
< 0.001 |
| Control |
16.0 (3–27) |
15.5 (5.0–27.0) |
16.0 (5–24) |
15.0 (4–22) |
11.5** (3.0–21.0) |
11.0** (1.0–27.0) |
11.0** (1.0–21.0) |
11.0** (1–16) |
< 0.001 |
|
Values are expressed as median (range). ANOVA, analysis of variance; APACHE II, acute physiological and chronic health evaluation; PCT, procalcitonin; SOFA, sequential organ failure assessment. *P < 0.05, **P < 0.01 when compared to Day 1. | |||||||||
Tugrul et al. Critical Care 2002 6:357 doi:10.1186/cc1523 |
|||||||||